Ironwood Pharmaceuticals, Inc. Class A
(NASDAQ : IRWD)

( )
IRWD PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
0.00%18.8814.1%$243.08m
SHPGShire PLC Sponsored ADR
0.00%134.060.4%$206.82m
SAGESAGE Therapeutics, Inc.
0.00%162.379.8%$109.73m
PRGOPerrigo Co. Plc
0.00%89.556.6%$84.14m
ICPTIntercept Pharmaceuticals, Inc.
0.00%61.1222.0%$72.23m
MDCOMedicines Company
0.00%33.1622.1%$61.90m
JAZZJazz Pharmaceuticals Plc
0.00%145.762.2%$57.13m
MNKMallinckrodt Plc
0.00%16.8018.5%$52.82m
UTHRUnited Therapeutics Corporation
0.00%134.9314.5%$52.29m
GWPHGW Pharmaceuticals PLC Sponsored ADR
0.00%131.017.6%$50.60m
CTLTCatalent Inc
0.00%43.382.6%$48.78m
ICLRICON Plc
0.00%115.014.1%$43.90m
CORTCorcept Therapeutics Incorporated.
0.00%15.985.5%$41.19m
PTLAPortola Pharmaceuticals, Inc.
0.00%47.697.8%$39.94m
PBHPrestige Brands Holdings, Inc.
0.00%35.233.8%$39.63m

Company Profile

Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which discovers, develops and intends to commercialize differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.